Kalso 1996.

Study characteristics
Methods	Design: cross‐over Duration: 4 weeks Assessment: baseline, 2 weeks, post‐intervention Country: Finland
Participants	Pain condition: cancer‐related neuropathic pain Population: women with chronic neuropathic pain following treatment for breast cancer Minimum pain intensity: no Inclusion criteria Moderate‐severity neuropathic pain following treatment for breast cancer Exclusion criteria: NR Total participants randomised: 20 Age in years (median, range): 56 (39‐72) Gender: 20/20 were female Pain duration in years (mean, SD): NR
Interventions	Placebo Inert Matched dosing to antidepressant Amitriptyline 100 mg TCA Forced titration to maximum tolerated dose or 100 mg/day
Outcomes	The article reported no useable data
Missing data methods	Completer‐only analysis
Funding source	Non‐pharmaceutical: The study was supported by the Academy of Finland (E.K., T.T.), the Paulo Foundation, Finland (E.K.) and the Centre for International Mobility (T.T.).
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods not specified
Allocation concealment (selection bias)	Unclear risk	Allocation procedure not specified
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	States double‐blind and matched dosing but doesn't specify other blinding procedures
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Self‐reported outcomes from participants, but unsure of blinding procedures
Incomplete outcome data (attrition bias) All outcomes	High risk	Completer‐only analysis. Withdrawal information doesn't specify in which period the participants withdrew Attrition Total: 5/20 (25.0%) Attrition per arm NR
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias were identified.